New drugs for treatment of ventricular arrhythmias.
This article has attempted to review selected clinical features of new antiarrhythmic agents for treatment of recurrent ventricular tachycardia and ventricular fibrillation. While it is apparent that the ideal antiarrhythmic agent does not exist, whether it be a new or old antiarrhythmic drug, effective and safe antiarrhythmic drug therapy can nevertheless be administered to many patients if the pharmacologic principles and properties described herein are carefully considered.
D000638:Amiodarone / Q000009:adverse effects / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001073:Aprindine / Q000009:adverse effects / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001949:Bretylium Compounds / Q000627:therapeutic use; D004206:Disopyramide / Q000009:adverse effects / Q000627:therapeutic use; D016700:Encainide; D006801:Humans; D008801:Mexiletine / Q000627:therapeutic use; D016677:Tocainide
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D008801:Mexiletine; D016677:Tocainide; D001073:Aprindine; D004206:Disopyramide; D000638:Amiodarone; D016700:Encainide